Korean Circ J.  2024 Jun;54(6):351-353. 10.4070/kcj.2024.0135.

The Newer-Generation DES, Really Nothing to Special?

• Joh HS

• KMID: 2556533
• DOI: http://doi.org/10.4070/kcj.2024.0135

Reference

1. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009; 2:291–299. PMID: 19463439.

2. Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol. 2013; 61:536–544. PMID: 23273394.

3. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol. 2003; 41:1283–1288. PMID: 12706922.

4. Kobayashi T, Sotomi Y, Suzuki S, et al. Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials. Cardiovasc Interv Ther. 2020; 35:250–258. PMID: 31422529.

5. Taglieri N, Bruno AG, Ghetti G, et al. Target lesion failure with current drug-eluting stents: evidence from a comprehensive network meta-analysis. JACC Cardiovasc Interv. 2020; 13:2868–2878. PMID: 33357524.

6. Iglesias JF, Roffi M, Losdat S, et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet. 2023; 402:1979–1990. PMID: 37898137.

7. Park S, Rha SW, Choi BG, et al. Efficacy and safety of sirolimus-eluting stent with biodegradable polymer Ultimaster™ in unselected Korean population: a multicenter, prospective, observational study from Korean Multicenter Ultimaster Registry. Korean Circ J. 2024; 54:339–350. PMID: 38767441.

8. Yoon CH, Jang J, Hur SH, et al. Osstem Cardiotec Centum stent versus Xience Alpine stent for de novo coronary artery lesion: a multicenter, randomized, parallel-designed, single blind test. Korean Circ J. 2022; 52:354–364. PMID: 35129319.

9. Kuramitsu S, Sonoda S, Ando K, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021; 36:158–168. PMID: 33439454.

10. Taniwaki M, Radu MD, Zaugg S, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016; 133:650–660. PMID: 26762519.

11. Coughlan JJ, Maeng M, Räber L, et al. Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. Rev Esp Cardiol (Engl Ed). 2022; 75:894–902. PMID: 35437213.